Pricing Log in Create free account

Capricor Therapeutics, Inc. (CAPR) vs Prothena Corporation plc (PRTA)

Capricor Therapeutics, Inc. and Prothena Corporation plc are both Biotechnology companies. Capricor Therapeutics, Inc. is the larger, with a market value of $479.1M against $421.5M — 1.1× the size. Prothena Corporation plc grew revenue faster over the last twelve months: 427.3% against −11.6%. Capricor Therapeutics, Inc. has the higher net margin (0.00% vs −80.7%) and the lower return on invested capital (−1,019.7% vs 0.00%). Across the 16 metrics below, Prothena Corporation plc leads on 10 and Capricor Therapeutics, Inc. on 6.

Valuation

Metric CAPR PRTA Biotechnology median
P/E n/m n/m 10.64
P/S 21.17 7.89 9.59
P/B 1.92 1.50 2.15
Price to free cash flow 3.60 n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales 11.13 2.60 9.45
Earnings yield (30.10%) (10.06%) (34.69%)
Free cash flow yield 27.76% (14.13%) (24.02%)

Profitability

Metric CAPR PRTA Biotechnology median
Gross margin 100.00% 100.00% 65.59%
Operating margin 0.00% (101.80%) 0.00%
Net margin 0.00% (80.67%) 0.00%
Free cash flow margin 0.00% (111.49%) 0.00%
Return on equity (73.70%) (14.39%) (51.96%)
Return on assets (51.53%) (12.54%) (46.06%)
Return on invested capital (1,019.73%) 0.00% 0.00%

Growth

Metric CAPR PRTA Biotechnology median
Revenue growth (TTM) (11.55%) 427.32% 4.59%
EPS growth (last fiscal year) (96.52%) (99.56%) 29.88%
Revenue growth, 5-year CAGR 85.83% 62.56% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CAPR PRTA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.35 25.05 4.86
Net debt to EBITDA 2.99 1.46 1.01

Dividend

Metric CAPR PRTA Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric CAPR PRTA Biotechnology median
Market cap 479.07m 421.47m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack